NeuroSense Therapeutics (NRSN) News Today → “Crash Insurance” For Your Retirement (From Unstoppable Prosperity) (Ad) Free NRSN Stock Alerts $1.21 +0.04 (+3.00%) (As of 03:20 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineNeuroSense Reports Positive Data Analysis From PARADIGM Trial With PrimeC In ALSmarkets.businessinsider.com - May 7 at 11:19 AMNeuroSense Announces New Positive Data Analysis from PARADIGM Clinical Trial Demonstrating Statistically Significant Slowing of Disease Progression in High-Risk ALS Patientsprnewswire.com - May 7 at 8:45 AMAnalyzing Phathom Pharmaceuticals (NASDAQ:PHAT) and NeuroSense Therapeutics (NASDAQ:NRSN)americanbankingnews.com - May 7 at 1:48 AMNeuroSense Therapeutics (NASDAQ:NRSN) Shares Up 4.7%americanbankingnews.com - May 4 at 3:16 AMNeuroSense Announces First Quarter 2024 Business Updateprnewswire.com - May 2 at 9:19 AMNeuroSense and Genetika+ Initiate Precision Medicine Collaboration Beginning with Ongoing Phase 2 Clinical Trial in Alzheimer's Diseasefinance.yahoo.com - April 22 at 8:41 AMNeuroSense reports positive ALS trial results, trends in biomarkersinvesting.com - April 19 at 11:23 PMNeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual Meetingprnewswire.com - April 18 at 8:30 AMNeuroSense to Present PARADIGM Data at the American Academy of Neurology Annual Meeting April 16, 2024finance.yahoo.com - April 12 at 10:35 AMNeuroSense to Present PARADIGM Data at the American Academy of Neurology Annual Meeting April 16, 2024prnewswire.com - April 12 at 8:30 AMNeuroSense Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placementprnewswire.com - April 10 at 7:16 PMNeuroSense Joins With Lonza To Advance Neurodegenerative Disease Treatments; Stock Up In Pre-marketmarkets.businessinsider.com - April 9 at 12:36 PMNeuroSense Collaborates with Lonza to Identify Exosome-based Biomarkers, in order to Advance Neurodegenerative Disease Treatments and Diagnosticsprnewswire.com - April 9 at 8:30 AMNeuroSense reports significant ALS trial results, year-end financialsuk.investing.com - April 7 at 7:25 PMNRSN Stock Earnings: NeuroSense Therapeutics Beats EPS for Q4 2023investorplace.com - April 5 at 9:01 PMNeuroSense Announces Year End 2023 Financial Results and Provides Business Updatefinance.yahoo.com - April 5 at 1:16 PMNeuroSense Therapeutics Ltd NRSNmorningstar.com - March 23 at 12:06 AMNeuroSense Reports Additional Positive Results from its ALS Phase 2b PARADIGM Trialfinance.yahoo.com - February 21 at 1:22 PMNeuroSense Reports Additional Positive Results from its ALS Phase 2b PARADIGM Trialprnewswire.com - February 21 at 8:30 AMNeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rulefinance.yahoo.com - February 7 at 1:25 PMNeuroSense Therapeutics Ltd: NeuroSense's ALS Drug Candidate Shows Promise In Recent Phase 2b Trial; More Milestones To Come In 2024finanznachrichten.de - January 30 at 7:17 PMNeuroSense’s (NASDAQ:NRSN) ALS Drug Candidate Shows Promise In Recent Phase 2b Trial; More Milestones To Come In 2024finance.yahoo.com - January 30 at 8:44 AMNeuroSense Recaps Positive 2023 Achievements Including Statistically Significant Slowing of Disease Progression in Phase 2b ALS Trial of PrimeC and Highlights Anticipated 2024 Catalystsfinance.yahoo.com - January 9 at 12:36 PMNeuroSense Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirementfinance.yahoo.com - January 4 at 1:25 AMNeurosense Therapeutics (NRSN) Earnings Dates & Reportsinvesting.com - December 19 at 1:36 PMAnalysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (CRSP) and Neurosense Therapeutics Ltd. (NRSN)markets.businessinsider.com - December 16 at 12:59 AMNeuroSense Reports New Data: Statistically Significant Clinical Efficacy in Phase 2b ALS Trialfinance.yahoo.com - December 14 at 1:38 PMAnalysts Are Bullish on Top Healthcare Stocks: Neurosense Therapeutics Ltd. (NRSN), Cerevel Therapeutics Holdings (CERE)markets.businessinsider.com - December 8 at 4:27 AMWe're A Little Worried About NeuroSense Therapeutics' (NASDAQ:NRSN) Cash Burn Ratefinance.yahoo.com - December 6 at 12:47 PMNeuroSense Therapeutics Sees Positive Safety Data in Phase 2 Trial for ALS Treatment, Shares Fallmarketwatch.com - December 5 at 9:47 AMNeuroSense Says Phase 2b ALS Trial Meets Primary And Secondary Endpointsmarkets.businessinsider.com - December 5 at 9:47 AMNeuroSense ALS candidate meets key study goalsmsn.com - December 5 at 9:47 AMNeuroSense's Phase 2b ALS Trial Achieves Primary Safety and Tolerability & Secondary Clinical Efficacy Endpointsfinance.yahoo.com - December 5 at 9:47 AMNeuroSense to Report Phase 2b ALS Topline Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints on December 5, 2023finance.yahoo.com - December 4 at 5:58 PMNeuroSense Therapeutics GAAP EPS of -$0.67msn.com - November 28 at 12:46 PMNeuroSense Therapeutics 9-Month Loss Narrowsmarkets.businessinsider.com - November 28 at 12:46 PMNeuroSense Announces Third Quarter 2023 Financial Results and Provides Business Updatefinance.yahoo.com - November 28 at 12:46 PMNeuroSense Therapeutics Concludes Successful Type D Meeting With FDA For ALS Treatmentmarkets.businessinsider.com - November 13 at 3:05 PMNeuroSense Receives U.S. FDA Confirmation of CMC Strategy for PrimeC in Preparation for Pivotal Phase 3 in ALS and Commercial Readinessfinance.yahoo.com - November 13 at 10:04 AMNeuroSense Completes Dosing of Last Patient in the Double-Blind Segment of Phase 2b ALS Trial: Topline Clinical Efficacy Results Expected December 2023finance.yahoo.com - November 6 at 8:38 AMNeuroSense Therapeutics to Participate in BIO-Europe Fallfinance.yahoo.com - November 1 at 10:23 AMRenowned ALS Researcher Confirms The Efficacy Of NeuroSense Therapeutics’ Lead Drug Candidate, PrimeCfinance.yahoo.com - October 19 at 12:49 PMmarketbeat.com - October 19 at 10:45 AMmarketbeat.com - October 19 at 10:32 AMNeuroSense CEO Provides Q3 2023 Updatefinance.yahoo.com - October 17 at 12:57 PMNeuroSense's PrimeC Demonstrates Outstanding Effect on ALS Survival in Innovative iPSC Modelfinance.yahoo.com - October 4 at 10:12 AMNeuroSense Therapeutics Ltd. Wtbarrons.com - September 25 at 8:46 PMEuropean Medicines Agency Grants NeuroSense SME Statusfinance.yahoo.com - September 20 at 1:34 PMNeuroSense Granted Patents in Europe, Japan, and Israel for its ALS Drug PrimeCfinance.yahoo.com - September 19 at 10:37 AMNeuroSense to Participate in Upcoming ALS Conferences: PACTALS in Malaysia and NEALS in the U.S.finance.yahoo.com - September 14 at 11:19 AM Get NeuroSense Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NRSN and its competitors with MarketBeat's FREE daily newsletter. Email Address Tech GIANT’s Plans to Revolutionize Crypto… (Ad)A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. NRSN Media Mentions By Week NRSN Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NRSN News Sentiment▼0.360.45▲Average Medical News Sentiment NRSN News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NRSN Articles This Week▼51▲NRSN Articles Average Week Get NeuroSense Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NRSN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: INDP News Today GLTO News Today APM News Today VINC News Today AVTX News Today TLPH News Today KALA News Today ORGS News Today BIVI News Today SLGL News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NRSN) was last updated on 5/10/2024 by MarketBeat.com Staff From Our Partners[Webinar] A Deep Dive into Options Volatility: Skew & Relative ValueOICThis 1 Biotech Stock has been shocking the marketsHuge AlertsTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaCharles Payne Demystifies OptionsUnstoppable ProsperityForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingYou need to know these two things about AI stocks ASAP…InvestorPlaceShocking: One AI startup's revenue could surge 4,735%Manward PressBiden Nomination CANCELED?The Freeport Society Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeuroSense Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
